Clinical study of myelodysplastic syndrome

Objective To investigate thalidomide,cyclosporine A,and arsenious acid combined treatment of myelodysplastic syndrome clinical efficacy.Methods 27 patients with myelodysplastic syndrome were randomly divided into control group 13 cases and 14 cases of treatment group.The control group to be male hormones,all-trans retinoic acid or a small-dose chemotherapy,interferon and other treatment for 6 months.The treatment group were treated with thalidomide,cyclosporine A,and arsenious acid combined treatment programs,according to patient tolerance,and used in conjunction to choose a maintenance dose of 3 to 6 months.Comparison of two groups of clinical efficacy and adverse reactions.Results The treatment group and control group,the total effective rate was 78.57% (11/14)and 46.15 % (6/13).The total effective rate,the difference was significant(P ＜ 0.05).The treatment group,adverse reactions and reversible dose-dependent manner mainly by symptomatic improvement after treatment.It was well tolerated in most patients,no treatment-related death.Conclusion Thalidomide,cyclosporine A,and arsenious acid combined treatment of myelodysplastic syndrome accurate,adverse reactions are mild,the patient can be tolerated. Key words: Myelodysplastic syndrome; Thalidomide; Cyclosporin A; Arsenic trioxide